HER2/ErbB2 Recombinant Rabbit mAb (S-3935-58)

Catalog Number: S0B6971 Application: WB, IHC-P Reactivity: Ms, Rt Conjugation: Unconjugated Brand: Starter

Price:

$100 USD

Size: 25μl 100μl

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Host	Rabbit
Antigen	HER2/ErbB2
Synonyms	Receptor tyrosine-protein kinase erbB-2; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; p185erbB2; CD340; Kiaa3023; Neu; Erbb2
Immunogen	Synthetic Peptide
Location	Cell membrane, Cytoplasm, Nucleus, Endosome
Accession	P70424
Clone Number	S-3935-58
Antibody Type	Recombinant mAb
Isotype	IgG
Application	WB, IHC-P
Reactivity	Ms, Rt
Positive Sample	4T1
Purification	Protein A
Concentration	0.5 mg/ml
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
Stability & Storage	12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution

application	dilution	species
WB	1:1000	Ms, Rt
IHC-P	1:2000	Ms, Rt

Background

HER2 (Human Epidermal Growth Factor Receptor 2), also known as ErbB2 or Neu, is a transmembrane tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR/ErbB) family, which plays a pivotal role in regulating cell growth, survival, and differentiation through signal transduction pathways such as PI3K/AKT and MAPK. Unlike other members of the ErbB family, HER2 has no known high-affinity ligand and exists in an open conformation ready for dimerization, primarily forming homodimers or heterodimers with other ErbB receptors like EGFR (ErbB1), ErbB3, or ErbB4 upon ligand binding to its partners, thereby amplifying downstream oncogenic signaling. The ERBB2 gene, located on chromosome 17q12, is frequently amplified or overexpressed in various malignancies, most notably in approximately 15–20% of invasive breast cancers, where it correlates with aggressive tumor behavior, increased proliferation, and poorer prognosis; however, this specific molecular profile has become a critical therapeutic target, leading to the development of highly effective targeted therapies including monoclonal antibodies like trastuzumab and pertuzumab, as well as tyrosine kinase inhibitors and antibody-drug conjugates, which have significantly improved clinical outcomes for patients with HER2-positive cancers.

Picture

Western Blot

WB result of HER2/ErbB2 Recombinant Rabbit mAb
Primary antibody: HER2/ErbB2 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: 4T1 whole cell lysate 20 µg
Secondary antibody: Goat Anti- rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 139 kDa
Observed MW: 190 kDa

Immunohistochemistry

IHC shows positive staining in paraffin-embedded mouse breast. Anti-HER2/ErbB2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

Negative control: IHC shows negative staining in paraffin-embedded mouse spleen. Anti-HER2/ErbB2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded rat breast. Anti-HER2/ErbB2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

Negative control: IHC shows negative staining in paraffin-embedded rat heart. Anti-HER2/ErbB2 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.